1605 related articles for article (PubMed ID: 34412685)
41. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
42. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
43. Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
Lee JB; Chen B; Vasic D; Law AD; Zhang L
Blood Rev; 2019 May; 35():18-31. PubMed ID: 30826141
[TBL] [Abstract][Full Text] [Related]
44. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
45. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
46. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Hu Y; Zhou Y; Zhang M; Zhao H; Wei G; Ge W; Cui Q; Mu Q; Chen G; Han L; Guo T; Cui J; Jiang X; Zheng X; Yu S; Li X; Zhang X; Chen M; Li X; Gao M; Wang K; Zu C; Zhang H; He X; Wang Y; Wang D; Ren J; Huang H
Cell Res; 2022 Nov; 32(11):995-1007. PubMed ID: 36151216
[TBL] [Abstract][Full Text] [Related]
47. Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies.
Rotiroti MC; Arcangeli S; Casucci M; Perriello V; Bondanza A; Biondi A; Tettamanti S; Biagi E
Hum Gene Ther; 2017 Mar; 28(3):231-241. PubMed ID: 27967241
[TBL] [Abstract][Full Text] [Related]
48. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
[TBL] [Abstract][Full Text] [Related]
49. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
50. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
51. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
52. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
53. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
54. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
55. Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
Hofmann S; Schubert ML; Wang L; He B; Neuber B; Dreger P; Müller-Tidow C; Schmitt M
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30736352
[TBL] [Abstract][Full Text] [Related]
56. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
57. Current Status of CAR T Cell Therapy for Leukemias.
Harris K; LaBelle JL; Bishop MR
Curr Treat Options Oncol; 2021 Jun; 22(7):62. PubMed ID: 34097135
[TBL] [Abstract][Full Text] [Related]
58. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
Wang X; Zhang Y; Xue S
Ann Hematol; 2024 Jun; 103(6):1843-1857. PubMed ID: 38381173
[TBL] [Abstract][Full Text] [Related]
59. Can Immune Therapy Cure Acute Myeloid Leukemia?
Gale RP
Curr Treat Options Oncol; 2023 May; 24(5):381-386. PubMed ID: 36949279
[TBL] [Abstract][Full Text] [Related]
60. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia.
Zhang H; Wang P; Li Z; He Y; Gan W; Jiang H
Clin Cancer Res; 2021 Jul; 27(13):3549-3555. PubMed ID: 33832948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]